Answers are grounded in this paper and cite their sources.
INTRODUCTION: Cost-effectiveness findings for adjuvant trastuzumab in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer vary across settings. We synthesized evidence using incremental net benefit (INB) and examined heterogeneity by country income group. METHODS: We systematically reviewed full economic evaluations published from 1998 to March 2025 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed. Scopus, and EBSCOhost were searched. Costs were standardized to 2024 purchasing power parity-adjusted international dollars (Int$). INB was pooled at a reference willingness-to-pay threshold of Int$100,000 per quality-adjusted life-year using random-effects models with restricted maximum likelihood estimation and Knapp-Hartung adjustment. RESULTS: Eighteen studies were included. Pooled INB was negative and imprecise in high-income settings (12 studies; approximately -Int$38,000), with the 95% confidence interval spanning zero. In middle-income settings (six studies), pooled INB was positive (approximately Int$90,000), with the confidence interval above zero. Heterogeneity was substantial (I2 ≈ 99%), and findings depended on the threshold. No low-income countries were represented. CONCLUSIONS: Estimates suggested favorable economic value in the included middle-income settings at the reference threshold. They do not establish affordability or generalizability across countries. Funding decisions require local assessment of economic value, budgets, and treatment capacity. PROTOCOL REGISTERED: PROSPERO, CRD42024623623.
No takes yet. Share an insight, caveat, or question.
Majam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: